Eribulin is a non-taxane synthetic analogue approved in many countries as thirdline treatment for the treatment of patients with metastatic breast cancer.In addition to its mitotic property,eribulin has non-mitotic pr...
Background:?Male breast cancer is rare, accounting for approximately 0.5% - 1.0% of all breast cancer cases;hormone-dependent luminal type male breast cancer is the most common. The proportion of hormone receptor-nega...
This study was supported by Eisai Korea Inc.(supplied eribulin),Dong-A ST Co.,Ltd.(supplied gemcitabine),and Samyang Biopharmaceuticals(supplied paclitaxel);This work was supported by a grant from the Ministry of Health and Welfare,Republic of Korea(HA17C0055);by the National R&D Program for Cancer Control,Ministry of Health and Welfare,Republic of Korea(1720150)
Background: A phase II clinical trial of the comparison between eribulin plus gemcitabine (EG) and paclitaxel plus gemcitabine (PG) as first-line chemotherapy for patients with metastatic breast cancer (MBC) found tha...
AIM: To discuss treatment with eribulin in clinical practice outside a clinical trial.METHODS: Archives of patients treated for metastatic breast cancer were reviewed and 21 patients treated with the new chemotherapeu...